Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Brian Michael Alexander, M.D.

Co-Author

This page shows the publications co-authored by Brian Alexander and Ayal Aizer.
Connection Strength

4.874
  1. Prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer. Neuro Oncol. 2017 08 01; 19(8):1015-1016.
    View in: PubMed
    Score: 0.748
  2. A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol. 2016 Feb; 18(2):269-74.
    View in: PubMed
    Score: 0.654
  3. Extent of resection and overall survival for patients with atypical and malignant meningioma. Cancer. 2015 Dec 15; 121(24):4376-81.
    View in: PubMed
    Score: 0.654
  4. Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro Oncol. 2014 Nov; 16(11):1547-53.
    View in: PubMed
    Score: 0.600
  5. Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation. JAMA Oncol. 2018 08 01; 4(8):1123-1124.
    View in: PubMed
    Score: 0.200
  6. Implications of Screening for Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer. JAMA Oncol. 2018 07 01; 4(7):1001-1003.
    View in: PubMed
    Score: 0.199
  7. Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. Radiother Oncol. 2018 03; 126(3):511-518.
    View in: PubMed
    Score: 0.194
  8. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017 Oct 19; 19(11):1511-1521.
    View in: PubMed
    Score: 0.190
  9. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. J Neurooncol. 2017 Dec; 135(3):581-591.
    View in: PubMed
    Score: 0.189
  10. Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study. JAMA Oncol. 2017 Aug 01; 3(8):1069-1077.
    View in: PubMed
    Score: 0.187
  11. Erratum to: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. J Neurooncol. 2017 05; 133(1):221.
    View in: PubMed
    Score: 0.184
  12. Whole brain radiotherapy for non-small cell lung cancer. Lancet. 2017 04 08; 389(10077):1394-1395.
    View in: PubMed
    Score: 0.183
  13. Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. J Neurooncol. 2016 09; 129(3):389-393.
    View in: PubMed
    Score: 0.174
  14. Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):384-9.
    View in: PubMed
    Score: 0.159
  15. Cancer-specific outcomes among young adults without health insurance. J Clin Oncol. 2014 Jul 01; 32(19):2025-30.
    View in: PubMed
    Score: 0.150
  16. Radiographic prediction of meningioma grade by semantic and radiomic features. PLoS One. 2017; 12(11):e0187908.
    View in: PubMed
    Score: 0.048
  17. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016 05; 18(5):649-55.
    View in: PubMed
    Score: 0.042
  18. Salvage whole brain radiotherapy or stereotactic radiosurgery after initial stereotactic radiosurgery for 1-4 brain metastases. J Neurooncol. 2015 Sep; 124(3):429-37.
    View in: PubMed
    Score: 0.040
  19. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015 Mar 10; 6(7):4704-16.
    View in: PubMed
    Score: 0.040
  20. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55.
    View in: PubMed
    Score: 0.040
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.